scholarly journals Intra-Anal Imiquimod Cream against Human Papillomavirus Infection in Men Who Have Sex with Men Living with HIV: A Single-Arm, Open-Label Pilot Study

2021 ◽  
Vol 10 (19) ◽  
pp. 4477
Author(s):  
Duygu Durukan ◽  
Tiffany R. Phillips ◽  
Gerald L. Murray ◽  
Jason J. Ong ◽  
Andrew E. Grulich ◽  
...  

Men who have sex with men (MSM) living with HIV have a high prevalence and incidence of anal high-risk human papillomavirus (hrHPV) and anal cancer. We conducted an open-label, single-arm pilot study to examine the tolerability of imiquimod cream among MSM aged ≥18 years, living with HIV, who tested positive for anal hrHPV at Melbourne Sexual Health Centre between April 2018 and June 2020. We instructed men to apply 6.25 mg imiquimod intra-anally and peri-anally 3 doses per week for 16 weeks (period 1) and then one dose per week for a further 48 weeks (period 2). Twenty-seven MSM enrolled in period 1 and 24 (86%) applied at least 50% of doses. All men reported adverse events (AEs), including 39.5% grade 1, 39.5% grade 2, and 21% grade 3 AEs on at least one occasion. Eighteen MSM (67%) temporarily stopped using imiquimod during period 1, most commonly due to local AEs (n = 11) such as irritation and itching. Eighteen MSM continued in period 2 and all applied at least 50% of doses with no treatment-limiting AEs reported. Imiquimod 3 doses per week caused local AEs in most men and was not well tolerated. In contrast, once-a-week application was well tolerated over 48-weeks with no treatment-limiting AEs.

2019 ◽  
Vol 35 (3) ◽  
pp. 267-275 ◽  
Author(s):  
Rebecca G. Nowak ◽  
Søren M. Bentzen ◽  
Jacques Ravel ◽  
Trevor A. Crowell ◽  
Wuese Dauda ◽  
...  

2017 ◽  
Vol 44 (3) ◽  
pp. 173-180
Author(s):  
Anantharam Raghavendran ◽  
Alexandra L. Hernandez ◽  
Shelly Lensing ◽  
Manu Gnanamony ◽  
Rajiv Karthik ◽  
...  

2012 ◽  
Vol 13 (5) ◽  
pp. 487-500 ◽  
Author(s):  
Dorothy A Machalek ◽  
Mary Poynten ◽  
Fengyi Jin ◽  
Christopher K Fairley ◽  
Annabelle Farnsworth ◽  
...  

2020 ◽  
Author(s):  
Holly B Fontenot ◽  
Bradley Patrick White ◽  
Joshua G Rosenberger ◽  
Hailee Lacasse ◽  
Chokdee Rutirasiri ◽  
...  

BACKGROUND Mobile app-based interventions have been identified as potential facilitators for vaccination among young men who have sex with men (MSM). OBJECTIVE This pilot study aimed to test the feasibility of a theoretically informed mobile health (mHealth) tool designed to reduce health disparities and facilitate human papillomavirus (HPV) vaccination among a sample of young MSM. METHODS The development of the mHealth tool was guided by previous research, implementation intention theory, and design thinking. We recruited MSM aged 18-26 years through a popular online dating app and linked participants to our mHealth tool, which provided HPV vaccine information and fostered access to care. RESULTS A total of 42 young MSM participated in this pilot study in Boston, Massachusetts. Participants reported variable HPV knowledge (ie, high knowledge of HPV risk factors and low knowledge of HPV-related cancer risks for men) and positive vaccine beliefs and attitudes. Of those who were either unvaccinated, not up to date, or did not report vaccine status, 23% (8/35) utilized the mHealth tool to obtain HPV vaccination. Participants primarily utilized the tool’s (1) educational components and (2) capabilities facilitating concrete vaccine action plans. CONCLUSIONS We recruited an underserved at-risk population of youth via an online dating app for our mHealth intervention that resulted in in-person health care delivery. This study was limited by enrollment challenges, including low willingness to download the mHealth tool to mobile devices.


Sign in / Sign up

Export Citation Format

Share Document